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in the PBSC product, we used a combination of CD34 selection
and ex vivo incubation with anti-CD3 antibody, which resulted in
a mean 5.2-log reduction of T cells (range, 4.7–6.3 log). The ﬁnal
PBSC products contained a mean of 9.94 (range, 4.8–13.0)  106
CD34 cells/kg and 1.34 (range, 0.06–4.54)  103 CD3 cells/
kg. The daily dose of CY was 200 mg/m2 in the ﬁrst 3 patients and
400 mg/m2 in the next 2 patients. The mean half-life (t1/2) of
CD3 cells in these patients was biphasic: 0.8 days from day7 to
day5 and 0.2 days from day5 to day3, correlating with ATG
administration. In contrast, the mean t1/2 of CD3 cells was 2.5
days in patients with hematologic malignancies receiving a myeloa-
blative preparative regimen of CY, busulfan, and etoposide. After
PBSCT, the median nadirs of WBC, ANC, and platelets were 1.2
(range, 0.4–2.0), 0.9 (range, 0.1–1.7) and 135 (range, 114–185) 
109/L, respectively. All patients are alive at a median of 8.5
months (range, 6.9 to 17.5 months) after PBSCT. Compared
with pre-PBSCT levels, Rodnan total skin score (TSS) decreased
by 4, 10, 11, and 15 points, respectively, in 4 patients and increased
by 8 points in 1 patient, who also developed SSc renal crisis
requiring hemodialysis at 12 months after PBSCT. Of 4 patients
with improved TSS, 1 has worsening polymyositis and 1 has
recurrence of palpable tendon friction rubs. Even at the lowest CY
dose, this immunosuppressive regimen provides signiﬁcantly
greater and more rapid T-cell kill than a conventional myeloabla-
tive regimen. The efﬁcacy of this regimen and TCD PBSCT in
SSc is encouraging. but requires longer follow-up and experience
with a larger number of patients.
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194
CONSOLIDATION AND MOBILIZATION OF PERIPHERAL BLOOD STEM
CELLS USING HIGH-DOSE CYTARABINE AND ETOPOSIDE IN ACUTE
MYELOID LEUKEMIA: A SINGLE INSTITUTIONAL EXPERIENCE
Shu, F., Bashey, A., Carrier, E., Castro, J., Holman, P., Lane, T.,
Medina, B., Corringham, S., Ball, E.D. Division of Blood and Marrow
Transplantation, Department of Medicine, and Moores’ UCSD Cancer
Center, University of California at San Diego, La Jolla, CA.
Autologous hematopoietic stem cell transplantation (autoHSCT)
as consolidation in ﬁrst complete remission (CR1) is an option for
patients with AML. Achieving adequate numbers of stem cells and
eradicating residual leukemia cells with acceptable toxicity repre-
sent two conﬂicting goals. Between May 2000 and May 2004, we
performed autoHSCT in 24 AML patients using a reduced dose
modiﬁcation of a cytarabine/etoposide regimen reported by Linker
(BBMT 6:50–57, 2000) as a consolidation and stem cell mobiliza-
tion regimen. Median age at the time of HSCT was 59 (range,
21–73; 50%  60 years). Most patients had intermediate-risk
(63%) or high-risk cytogenetics (25%). All patients but 1 were in
CR1 before autoHSCT. After induction chemotherapy, 12 pa-
tients proceeded to consolidation/mobilization. Twleve patients
had additional consolidation with cytarabine-based regimens (8
with 1 consolidation and 4 with 2 consolidations). All patients then
received etoposide (5 mg/kg IV every 12 hours) and cytarabine (2
g/m2 IV every 12 hours) for 3 days instead of the 4 days described
by Linker. Patients received G-CSF (10 g/kg SC) on day 14 until
the WBC count was 10,000. The median number of CD34
stem cells collected was 5.9  106/kg (range, 1.3–75.5). Some 92%
of patients received busulfan and cyclophosphamide as a condi-
tioning regimen. There were no treatment-related deaths. En-
graftment was rapid: WBC 1000 in 11.5 days (range, 9–19 days),
ANC 500 in 12 days (range, 10–21 days), and platelets 50,000
in 17 days (range, 11–214 days). Median follow-up is 13.6 months
(range, 2–52 months). Eleven patients (46%) relapsed at a median
of 5.4 months (range 1.2–27.5 months). Median disease-free sur-
vival (DFS) for all patients is 27.5 months. Patients with interme-
diate- and high-risk cytogenetics had a 1-year DFS of 54% and
50%, respectively. Patients receiving at least 1 consolidation before
the mobilization regimen had 1-year DFS and overall survival (OS)
of 56% and 73%, respectively compared with 46% and 64% for
those proceeding directly from induction to mobilization. Our data
suggest that autoHSCT using reduced doses of cytarabine and
etoposide as a consolidation and mobilization regimen is safe and
effective at achieving engraftment, and is associated with encour-
aging outcomes in patients with intermediate- to high-risk cyto-
genetics. At least 1 consolidation before the mobilization/consoli-
dation regimen may be associated with superior outcome.
Prospective trials with larger numbers of patients are needed to
validate our preliminary ﬁndings.
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AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR HIGH-RISK
PEDIATRIC SOLID TUMORS
Fraser, C.J.1, Weigel, B.J.1, John, P.P.2, Todd, D.E.1, Kevin, B.S.1,
Michael, V.R.1 1University of Minnesota, Minneapolis, MN; 2Cincin-
nati Children’s Hospital Medical Center, Cincinnati, OH.
Aim: The purpose of this study was to determine the toxicity of
treatment with high-dose alkylating agents followed by ASCT, to
monitor treatment response and to promote disease free survival in
a group of pediatric patients with high risk solid tumors.Methods:
A total of 36 patients with solid tumors having disseminated disease
at diagnosis or following relapse were treated on 2 consecutive
autologous transplantation protocols at the University of Minne-
sota between May 1995 and March 2004. Preliminary data on 11 of
these patients have already been reported. The age range of the
patients was 2–26 years. Of the 36 patients, 20 had a diagnosis of
a Ewing’s family tumor (16 Ewing’s sarcoma and 4 desmoplastic
small round cell tumor). Other diagnoses included rhabdomyosar-
coma (in 3 patients), Wilm’s tumor (in 2), medulloblastoma (in 2),
and ependymoma, atypical teratoid rhabdoid tumor, glioblastoma
multiforme, osteosarcoma, hepatoblastoma, retinoblastoma, cervi-
cal chordoma, ovarian small cell carcinoma and ovarian mixed
anaplastic germ cell tumor each in 1 patient. Patients were eligible
for transplantation if they had a complete response (CR) (18
patients) or a very good partial response with nonprogressive
disease (18 patients). Conditioning therapy consisted of either oral
busulfan (12 mg/kg) or intravenous busulfan (9.6 mg/kg  4 years;
12 mg/kg  4 years), melphalan (100 mg/m2) and thiotepa (500
mg/m2). Thirteen patients received the chemoprotectant amifos-
tine. All patients received G-CSF until neutrophil engraftment.
Twenty patients received PBSC, 15 patients received autologous
bone marrow, and 1 patient received syngeneic marrow. Results:
Median time to neutrophil engraftment, deﬁned as the ﬁrst of 3
consecutive days of an ANC  0.5  109/L, was 11 days (range,
9–56 days). Overall survival was 63% (range, 47%-79%) at 1 year
and 33% (range, 16%-50%) at 3 years. Disease-free survival was
28% (range, 13%-43%) at 3 years. Median follow-up among sur-
vivors is 3.5 years (range, 0.6–7.9 years). Three-year overall sur-
vival for Ewing’s family tumors was signiﬁcantly better than for all
other diagnoses (54% vs 13%; P .03). Three-year overall survival
was signiﬁcantly better for those patients transplanted after CR
(48% vs 12%; P  .03). There were 2 toxic deaths attributed to
veno-occlusive disease. Conclusions: Our data indicate that
ASCT after high-dose alkylating agent therapy has acceptable
toxicity and should be considered as consolidation therapy for
patients with high-risk Ewing’s family tumors. The effectiveness of
this therapy for other diagnoses appears to be limited.
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TANDEM AUTOGRAFTS FOR MULTIPLE MYELOMA PATIENTS USING
TWO DIFFERENT CONDITIONING REGIMENS: AN INTERIM ANALYSIS
Liu, H.1, Roberts, C.2, Pumphrey, P.2, Wingard, J.R.1, Moreb, J.S.1
1University of Florida College of Medicine, Gainesville, FL; 2Shands
Hospital at University of Florida, Gainesville, FL.
Autologous stem cell transplantation (ASCT) has become a stan-
dard therapy for multiple myeloma (MM) patients. In the current
study, we evaluated the toxicity and efﬁcacy of tandem autografts
Poster Session II
65BB&MT
for MM patients using non–melphalan-based conditioning regi-
mens. Patients were enrolled in the study after exhibiting response
to induction therapy and meeting eligibility criteria. The treatment
plan was designed to harvest a dose of 10  106 peripheral blood
CD34 cells/kg for the planned 2 transplants; however, a second
ASCT would be pursued only in the event that CR/VGPR was not
achieved after the ﬁrst ASCT. The conditioning regimen for the
ﬁrst ASCT included oral busulfan 0.75 mg/kg every 6 hours on
days 8 through 5, intravenous (IV) etoposide 10 mg/kg/day on
days 4 to 2, and cyclosphosphamide (CP) IV 60 mg/kg/day on
days on 3 and 2. The conditioning regimen for the second
ASCT included 96-hour (days 6 through 3) continuous infu-
sion of CP (6 g/m2) and total body irradiation of 600 cGy in 4
fractions (days 2 and 1), followed by reinfusion of stem cell
product. Forty evaluable patients have been analyzed. The median
patient age was 56 years, with a median time from diagnosis to ﬁrst
ASCT of 8.7 months. Thirteen patients met the criteria for high-
risk myeloma. After the ﬁrst ASCT, 15 patients had CR/VGPR, 11
proceeded to the second ASCT, 8 refused to proceed to the second
ASCT, and 6 others did not proceed for other reasons. All patients
were offered posttransplantation maintenance therapy and treated
with monthly bisphosphonate. There was no treatment-related
mortality. Overall, 2 of 29 patients who underwent single trans-
plantation died 17 and 15 months after the transplantation second-
ary to disease progression (DP) or pneumonia. Three out of 11
patients who underwent tandem transplantations died, 2 of DP at
15 and 26 months after the second transplantation, and 1 patient
with a history of gastric bypass died of cryptogenic cirrhosis/liver
failure at 7 months. The median time between the two ASCTs was
107 days. Improvement in response category occurred in 34% after
the ﬁrst ASCT and in a total of 55% after the second ASCT. The
overall CR/VGPR rate was 20% before ASCT, 52% after single
transplantation, and 64% after double transplantation. At a median
follow-up of 15 months from the last ASCT, PFS was 14 months
after single transplantation (n  29) and 23 months after double
transplantation (n  11) (P  .46). The overall survival has not
been reached for both groups. The median PFS was 41 months for
all those with CR/VGPR, versus 26 months for all others (P 
.0146). In conclusion, non–melphalan-based conditioning regi-
mens seem to be effective and safe.
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CD34CD38 AND CD34HLADR CONTENTS IN BMSC GRAFTS
CORRELATE WITH SHORT-TERM ENGRAFTMENT BUT HAVE NO INFLU-
ENCE ON LONG-TERM HEMATOPOIETIC RECOVERY IN PATIENTS WHO
RECEIVED AUTOLOGOUS BONE MARROW TRANSPLANTATION
Zubair, A.C.1, Kao, G.2, Ritz, J.2 1Mayo Clinic, Jacksonville, FL;
2Dana Farber Cancer Institute, Boston, MA.
Previous animal and human studies have demonstrated that the
number of CD34 subsets such as CD34CD38 and
CD34HLADR subsets in stem cell grafts is signiﬁcantly
associated with the speed of short-term hematopoietic reconstruc-
tion (SHR). The aim of this study was to determine whether these
CD34 subsets predict long-term hematopoietic reconstitution
(LHR) in recipients of autologous bone marrow transplantation
(ABMT).
We have examined 53 lymphoma patients who received ABMTs
to determine if total mononuclear cell dose, CFU-GM, CD34
cell dose and CD34 cell subsets (CD34CD38 and
CD34HLADR) correlate with both SHR and LHR. Time to
neutrophil engraftment (TNE) and time to platelet engraftment
(TPE) were used to measure SHR, and platelet count was used as
an indicator of LHR at day 100 and 1 year post-ABMT. A total of
42 and 38 patients were analyzed at day 100 and 1 year post-
transplant, respectively. Patients were excluded either because they
were deceased or there was lack of follow-up data. Using a univar-
iate unadjusted logistic regression analysis, all of the predictor
variables were signiﬁcantly associated with SHR. However, at day
100, only CFU-GM and CD34 cell dose signiﬁcantly predicted
LHR. In addition, at 1 year post-ABMT, only CD34 cell dose
predicted LHR. CD34 cell dose maintained its signiﬁcance in
multivariate analysis adjusting for age, sex, and disease. None of
the CD34 cell subsets predicted LHR.
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ELEVATED MEAN CORPUSCULAR VOLUME (MCV) FOLLOWING AUTOL-
OGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: INCIDENCE
AND SIGNIFICANCE
Hamadani, M.H.1, Kamble, R.1,2, Sethi, S.1,2, Kharfan-Dabaja, M.1,2,
Kern, W.3, Ozer, H.1,2, Selby, G.B.1,2 1Department of Internal Med-
icine, Oklahoma University Health Sciences Center, Oklahoma City,
OK; 2Section of Hematology & Oncology, Oklahoma City, OK; 3Depart-
ment of Pathology, Oklahoma University Health Sciences Center, Okla-
homa City, OK.
Background: A relationship between macrocytosis and the risk
of secondary leukemia has been suggested in long-term cancer
survivors after chemotherapy. The incidence and signiﬁcance of
MCV elevation after high-dose chemotherapy and autologous he-
matopoietic stem cell transplantation (ASCT) is unknown. Meth-
ods: A retrospective analysis of 130 consecutive patients who
underwent ASCT between January 1999 and December 2003 was
performed. Complete blood count proﬁle was analyzed at trans-
plantation and then at 6 months, 1 year, and yearly after transplan-
tation. Patients with relapse of disease within 6 months of trans-
plantation were excluded. Sixty-three of 130 (48%) patients were
eligible for the study. Patient characteristics and time to achieve
long-term hematologic recovery (hemoglobin 12 g/dL, WBC
4000/mm3, platelets  150,000/mm3) were analyzed. When avail-
able, history of alcohol abuse, abnormal liver function, thyroid
function, vitamin B12, and folate deﬁciency were recorded. Re-
sults: At median follow-up of 22 months (range, 6–58 months), 33
of 63 (52.8%) patients displayed elevated MCV 6 months post-
transplantation. The median patients age was 12 years (range, 1–76
years). Four patients underwent double transplantation. Median
time to engraftment for neutrophils and platelets was 12 and 19
days, respectively. The median time to trilineage hematologic
normalcy was 289 days; 27 of 33 (81%) patients had suboptimal
long-term hematopoietic recovery at 6 months (WBC, 5 months;
hemoglobin, 14 months; platelets, 22 months).
At 6 months posttransplantation, 15 of 43 (35%) adult patients
displayed elevated MCV (normal, 81–99 ﬂ); the mean pretrans-
plantation MCV of 97.5 ﬂ increased to 102.7 ﬂ (P  .004). Of the
20 pediatric patients, 18 (91%) displayed elevated MCV at 6
months posttransplantation; mean pretransplantation MCV of 90.8
ﬂ increased to 94.1 ﬂ (P  .001). Persistent MCV elevation was
observed in 17 of 26 patients (65%) at 1 years posttransplantation
and in 7 of 14 patients (50%) at 2 years posttransplantation.
Pretransplantation red cell distribution width (RDW) was higher
pretransplantation (63%) than at 6 months posttransplantation
(45%). Further investigations of MCV elevation available in 10
patients were negative. No patients developed MDS or leukemia.
Conclusion: MCV elevation after high-dose chemotherapy and
ASCT is frequent, with an incidence of 52.8%. Macrocytosis
occurred unrelated to anemia; routine workup of macrocytosis is
unnecessary. Longer follow-up is needed to determine its signiﬁ-
cance, if any.
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MYELOABLATIVE CHEMOTHERAPY AND AUTOLOGOUS PERIPHERAL
STEM CELL TRANSPLANTATION WITHOUT THE USE OF BLOOD PROD-
UCTS
Jamal, F., Lim, S.W., Vescio, R., Pepkowitz, S., Van Strien, P.,
Hoshal, K., Lill, M.C. Cedars-Sinai Medical Center, Los Angeles, CA.
Background: Refusal of blood products poses a treatment chal-
lenge for Jehovah’s Witness patients whose malignant diseases
require high dose chemotherapy. We report our ﬁndings from a
series of Jehovah’s Witness patients who were enrolled in our
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